Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral; Safety Risk Overwhelms Promising Efficacy
-
Chardan Capital Markets Starts HealthEquity, Inc (HQY) at Buy
-
Pre-Open Stock Movers 12/12: (AKAO) (AIQ) (CSOD) Higher; (OPHT) (ALXN) (VIAB) Lower (more...)
-
PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial
-
Regeneron (REGN) Gains Early on Ophthotech Wet AMD Failure
-
Chardan Capital Markets Downgrades Ophthotech Corp (OPHT) to Neutral
-
Chardan Capital Markets Upgrades Regeneron Pharma (REGN) to Neutral
-
Palatin Technologies Closes on $16.5 Million Financing
-
Chardan Capital Markets Reiterates Buy on Eyegate Pharma (EYEG) Following Study Results
-
Chardan Capital Markets Reiterates Buy on Vuzix Corp. (VUZI)
-
Chardan Capital Markets Positive on Alnylam (ALNY) as ASH Data Reinforces Potential for RNAi Across Hemophilia and AIP
-
Vuzix Announces Closing of $14,500,000 Common Stock Offering
-
VBL Therapeutics (VBLT) Reports $20M at the Market Offering of Ordinary Shares
-
Palatin Technologies (PTN) Prices $16.5M Common Stock, Warrants Offering
-
Palatin Technologies Announces Pricing of Public Offering of Common Stock and Warrants
-
Palatin Technologies (PTN) Confirms Proposed Offering of Common Stock and Warrants
-
Palatin Technologies Announces Proposed Public Offering of Common Stock and Warrants
-
Notable Analyst Rating Changes 11/30: (UNH) (CE) (GS) Upgraded; (GRA) (FCX) (DLTH) Downgraded
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $89 at Chardan Capital Markets Following Arrowhead's RNAi Program Discontinuations
-
Chardan Capital Markets Starts WageWorks (WAGE) at Buy
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Amid Arrowhead Hepatitis B Program Discontinuations
-
Chardan Capital Markets Downgrades Arrowhead Research (ARWR) to Neutral on EX-1 RNAi Program Discontinuations
-
Vuzix Corp. (VUZI) to Offer 2M Shares of Common Stock for Proceeds of $14.5M
-
Vuzix Announces $14,500,000 Common Stock Offering
-
Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy
-
Chardan Capital Markets Remains Bullish on Vuzix Corp. (VUZI) as Intel Steps Back Relationship
-
Notable Analyst Rating Changes 11/16: (DIS) (FOSL) (PAAS) Upgraded; (NOK) (WDR) (NE) Downgraded
-
Chardan Capital Markets Starts Teladoc (TDOC) at Buy; Sees 40% Upside
-
uniQure (QURE) PT Cut to $12 at Chardan Capital Markets; 'Buy' Maintained on Simplification
-
Chardan Capital Markets Reiterates Buy on Vuzix Corp. (VUZI) Following 3Q
-
NICE Systems (NICE): Chardan Reiterates Buy After Strong Earnings But Before InContact Combination - Chardan
-
Regeneron (REGN): Reluctance To Discuss Pricing Causes a PT Revision - Chardan
-
Spark Therapeutics (ONCE) PT Lowered 14% at Chardan Capital Markets as They See Better Value Elsewhere in AAV GT
-
Notable Analyst Rating Changes 11/4: (ACHN) (MMC) (HCP) Upgraded; (AXL) (BRO) (WFM) Downgraded
-
Chardan Capital Markets Maintains Bullish View on Cogent (COGT) on Expected Strong Revenue Growth and Margin Expansion
-
Chardan Capital Markets Upgrades Achillion Pharmaceuticals (ACHN) to Neutral Following Underperformance
-
Achillion Pharmaceuticals (ACHN) Sell Rating Reiterated at Chardan Capital Markets Amid ACH-4471 Risks
-
Buy The KEYW Holding (KEYW) on Weakness - Chardan Capital Markets
-
Chardan Capital Markets Downgrades Opexa Therapeutics (OPXA) to Neutral
-
Chardan Capital Markets Starts Astrotech Corporation (ASTC) at Buy
-
Notable Analyst Rating Changes 10/25: (MKC) (FE) (CHK) Upgraded; (VFC) (ARIA) (OCN) Downgraded
-
Pre-Open Stock Movers 10/25: (SAEX) (CWEI) (SWFT) Higher; (DPRX) (CRBP) (UA) Lower (more...)
-
UPDATE: Chardan Capital Markets Starts Clovis Oncology (CLVS) at 'Sell' With Price Target of $15
-
22nd Century Group Announces Closing of $11.4 Million Above-Market Registered Direct Offering
-
PlacementTracker Publishes Q3 2016 Private Placement Market League Tables
-
Inventergy Announces Closing of $6.0 Million Public Offering
-
22nd Century Group (XXII) Enters $11.4M Share Registered Direct Offering
-
22nd Century Group Announces Above-Market Offering for $11.4 Million
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Neutral
-
Notable Mergers and Acquisitions 10/10: (CPN) (PRMW) (LLL) (AYA)

